| IMMUNITYBIO INC. DL-,0001 |
| USA |
| Gesundheit |
| US45256X1037 / A2QQ2E |
| 26CA (Frankfurt) / IBRX (NASDAQ) |
| FRA:26CA, ETR:26CA, 26CA:GR, NASDAQ:IBRX |
| - |
| https://immunitybio.com/ |
|
ImmunityBio Inc. is a biotechnology company focused on developing and commercializing immunotherapies that activate the body’s innate and adaptive immune systems. Its current portfolio centers on ANKTIVA, a lead biologic product used with BCG for a..
>Volltext.. |
| 9944.5 Mio. EUR |
| 10708.67 Mio. EUR |
| 148.01 Mio. EUR |
| -209.98 Mio. EUR |
| -885.95 Mio. EUR |
| -0.87 EUR |
| 1096.68 Mio. EUR |
| 67.56 Mio. EUR |
| -250.99 Mio. EUR |
| 4.66 |
| 202.13% |
| -178.83% |
| - |
| - |
| - |
| IMMUNITYBIO |
| 14.10.26 |
|